Viral hepatitis

Viral hepatitis

Introduction

Viral hepatitis refers to inflammation of the liver caused by infection with one of the five major hepatitis viruses: Hepatitis A, B, C, D, and E. These viruses target liver cells, leading to varying degrees of liver inflammation, hepatocyte injury, and potential long-term complications such as cirrhosis and hepatocellular carcinoma (HCC).


Hepatitis A

  • Definition:
    • Acute viral hepatitis caused by the Hepatitis A virus (HAV).
    • Transmitted via the faecal-oral route (contaminated food/water).
  • Course:
    • Incubation: 2–6 weeks
    • Symptoms:
      • Fatigue, nausea, vomiting, abdominal pain
      • Jaundice
    • Resolution:
      • Self-limiting; most cases resolve without complications.
      • No chronic infection.
  • Diagnosis
    • Positive anti-HAV IgM (acute infection)
    • Positive anti-HAV IgG (past infection or immunity)
  • Management:
    • Supportive care (hydration, rest).
    • Post-exposure prophylaxis:
      • HAV vaccine and/or immune globulin within 2 weeks of exposure.
  • Prevention:
    • HAV vaccine available
      • recommended for travellers and at-risk populations such as men who have sex with men.

Hepatitis B

  • Definition
    • Hepatitis B is a viral infection caused by the Hepatitis B virus (HBV).
    • Transmitted via blood and body fluids (e.g., sexual contact, IVDU, vertical transmission).
  • Course
    1. Acute Infection
      • Incubation: 1–6 months
      • Symptoms: Often asymptomatic; may cause fatigue, nausea, jaundice, and right upper quadrant pain.
      • Severe Cases: Can lead to fulminant hepatitis (rare but life-threatening).
      • Resolution: Most adults recover completely, developing anti-HBs antibodies (immunity).
    2. Chronic Infection
      • More common in infants (90%) than adults (5%).
      • Two types:
        • Inactive carrier state: Low viral replication, minimal liver damage.
        • Chronic active hepatitis: Persistent liver inflammation, increased risk of cirrhosis & hepatocellular carcinoma (HCC).
  • Investigations
    • Hepatitis B serology
    • Screen for other blood-borne viruses (HCV, HIV) and other STIs
  • Complications
    • Chronic hepatitis → “Ground-glass” hepatocytes on biopsy.
    • Hepatocellular carcinoma (HCC).
    • Cirrhosis & Liver failure.
    • Extrahepatic: Glomerulonephritis, polyarteritis nodosa, cryoglobulinemia.
  • Management
    • Acute HBV:
      • Supportive care (fluids, rest)
      • Most cases resolve spontaneously
    • Chronic HBV:
      • First-line antiviral: Pegylated interferon-alpha.
      • Other options: Tenofovir, Entecavir (used long-term to suppress virus).
      • Screen for HCC (liver cancer) with ultrasound & FibroScan.
      • Liver transplant for end stage liver disease
    • Additional management
      • Lifestyle changes: Avoid alcohol, stop smoking.
      • Have a low threshold for screening patients who are are risk of developing hepatitis B
      • Notify public health England as it a notifiable disease
      • Educate the patient about reducing transmission and informing potential risk contacts
  • Screening and diagnosis
    • All pregnant women screened for HBV
    • Screen high-risk individuals (e.g., IVDU, MSM, healthcare workers)
  • Vaccination
    • Part of UK routine schedule (6-in-1 vaccine) at 2, 3, and 4 months.
    • At-risk groups (HCWs, IVDUs, sex workers, CKD, liver disease, prisoners) should be vaccinated.
    • Booster at 5 years for at-risk individuals if anti-HBs < 100 mlU/ml.
  • Pregnancy and newborns
    • All pregnant women are screened.
    • If mother is HBV-positive,
      • Newborns gets vaccine
      • HBIG at birth
      • extra doses at 1 & 12 months.
    • Breastfeeding is safe if infant is vaccinated.

Hepatitis C

  • Definition:
    • Viral hepatitis caused by HCV, a single-stranded RNA virus.
    • Transmitted through blood contact (IVDU, transfusion, sexual)
  • Course:
    • Acute:
      • Incubation: 2–12 weeks
      • Often asymptomatic
      • 80% progress to chronic infection
    • Chronic:
      • Progressive liver damage → cirrhosis (20–30%)
      • Increased risk of HCC
  • Diagnosis
    • HCV RNA – Confirms active infection
    • Anti-HCV antibodies – Confirms past or current infection
  • Management:
    • Direct-acting antivirals (e.g., sofosbuvir, ledipasvir)
      • 95% cure rate

    • Screen for HCC and liver fibrosis regularly

Hepatitis D

  • Definition:
    • Caused by the Hepatitis D virus (HDV), a defective RNA virus that requires HBV to replicate.
  • Course:
    • Co-infection:
      • Acute HBV and HDV infection leading to severe hepatitis
    • Superinfection:
      • Chronic HBV + HDV leading to rapid progression to cirrhosis
  • Diagnosis
    • Positive HDV RNA
    • Positive anti-HDV antibodies
  • Management:
    • Pegylated interferon-alpha (poor response)
    • HBV suppression reduces HDV activity
    • Liver transplant if severe cirrhosis

Hepatitis E

  • Definition:
    • Caused by Hepatitis E virus (HEV)
    • Faecal-oral transmission (contaminated food/water)
  • Course:
    • Acute:
      • Incubation: 2–8 weeks
      • Self-limiting in most cases
    • Severe in Pregnancy:
      • Risk of fulminant hepatitis and liver failure (especially in 3rd trimester)
  • Diagnosis
    • Anti-HEV IgM – Acute infection
    • HEV RNA – Confirms active infection
  • Management:
    • Supportive care
    • Avoid immunosuppressive drugs if chronic infection in immunocompromised
  • Prevention
    • Improve sanitation and water quality
    • HEV vaccine available in some countries (not globally licensed)

FAQ from our users

Can hepatitis B and C be cured?
  • HBV cannot be eradicated, but viral load can be suppressed.
  • HCV can be cured with direct-acting antivirals.

Common pitfalls in a clinical setting

Common pitfalls in a clinical setting
  • Have a low threshold for screening patients who are are risk of developing hepatitis B
  • A patient with hepatitis B becomes suddenly very unwell, consider if they are now suffering co-infection with Hepatitis D.